Intestinal Research

Search: Intest Res Search

CLOSE

Intestinal Research

‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).

The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Review

December 1, 2020

Gut microbiome and checkpoint inhibitor colitis

Kanika Sehgal, Sahil Khanna

Intest Res. 2021;19(4):360-364.

Immune checkpoint inhibitor therapies such as ipilimumab, are increasingly being used as a treatment option for a variety of cancers, including metastatic melanoma and have demonstrated effectively a prolonged survival....

Review

November 25, 2020

Crohn’s disease at radiological imaging: focus on techniques and intestinal tract

Giuseppe Cicero, Silvio Mazziotti

Intest Res. 2021;19(4):365-378.

Over recent years, inflammatory bowel diseases have become an issue of increased attention in daily clinical practice, due to both a rising incidence and improved imaging capability in detection. In...

Review

November 6, 2020

An overview of the gut side of the SARS-CoV-2 infection

Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.

Intest Res. 2021;19(4):379-385.

In late 2019, an outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initiated in Wuhan, Hubei province, China. The major clinical symptoms described for coronavirus disease...

Original Article

December 1, 2020

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)

Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.

Intest Res. 2021;19(4):386-397.

Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC). Methods: This sub-analysis was conducted on data...

Original Article

November 20, 2020

Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease

Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.

Intest Res. 2021;19(4):398-407.

Background/Aims: Information on pediatric inflammatory bowel disease (PIBD) and very early onset IBD (VEOIBD) are sparse in India, where IBD is emerging. We aimed to evaluate characteristics of VEOIBD and...

Original Article

November 20, 2020

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study

Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.

Intest Res. 2021;19(4):408-418.

Background/Aims: Crohn’s disease is a chronic disorder; therefore, it is essential to investigate long-term safety and efficacy of treatments. This study assessed the safety and effectiveness of adalimumab for up...

Original Article

November 10, 2020

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study

Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.

Intest Res. 2021;19(4):419-429.

Background/Aims: Adalimumab has been shown to induce and maintain clinical remission in patients with moderate to severe ulcerative colitis (UC). However, no large-scale population-based studies have been performed in Japan....

Original Article

November 9, 2020

Clinical characteristics of inflammatory bowel disease patients with immunoglobulin A nephropathy

Ryohei Hayashi, Yoshitaka Ueno, Shinji Tanaka, et al.

Intest Res. 2021;19(4):430-437.

Background/Aims: Inflammatory bowel disease (IBD) is a chronic inflammation of the gastrointestinal tract. Some patients with this condition have been reported to present with immunoglobulin A nephropathy (IgAN), a renal...

Original Article

November 6, 2020

High mucosal cytomegalovirus DNA helps predict adverse short-term outcome in acute severe ulcerative colitis

Saransh Jain, Divya Namdeo, Pabitra Sahu, et al.

Intest Res. 2021;19(4):438-447.

Background/Aims: Predictors of short-term outcome of intravenous (IV) steroid therapy in acute severe ulcerative colitis (ASUC) have been well described, but the impact of cytomegalovirus (CMV) infection as a predictor...

Original Article

August 18, 2020

Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, et al.

Intest Res. 2021;19(4):448-460.

Background/Aims: A subgroup analysis was conducted in Japanese patients with moderate to severe ulcerative colitis (UC) enrolled in the phase 3 VISIBLE 1 study, which evaluated the safety and efficacy...

Original Article

August 18, 2020

Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?

Eirini Theodoraki, Eleni Orfanoudaki, Kalliopi Foteinogiannopoulou, et al.

Intest Res. 2021;19(4):461-467.

Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs)...

Current Issue: Volume 19(4); Oct 2021

This archive contains links to the full-text of all issues of Intest Res.

All issues

Vol. 19
2021

v.19(1)
Jan 2021

v.19(2)
Apr 2021

v.19(3)
Jul 2021

v.19(4)
Oct 2021

Vol. 18
2020

v.18(1)
Jan 2020

v.18(2)
Apr 2020

v.18(3)
Jul 2020

v.18(4)
Oct 2020

Vol. 17
2019

v.17(1)
Jan 2019

v.17(2)
Apr 2019

v.17(3)
Jul 2019

v.17(4)
Oct 2019

Vol. 16
2018

v.16(1)
Jan 2018

v.16(2)
Apr 2018

v.16(3)
Jul 2018

v.16(4)
Oct 2018

Vol. 15
2017

v.15(1)
Jan 2017

v.15(2)
Apr 2017

v.15(3)
Jul 2017

v.15(4)
Oct 2017

Vol. 14
2016

v.14(1)
Jan 2016

v.14(2)
Apr 2016

v.14(3)
Jul 2016

v.14(4)
Oct 2016

Vol. 13
2015

v.13(1)
Jan 2015

v.13(2)
Apr 2015

v.13(3)
Jul 2015

v.13(4)
Oct 2015

Vol. 12
2014

v.12(1)
Jan 2014

v.12(2)
Apr 2014

v.12(3)
Jul 2014

v.12(4)
Oct 2014

Vol. 11
2013

v.11(1)
Jan 2013

v.11(2)
Apr 2013

v.11(3)
Jul 2013

v.11(4)
Oct 2013

Vol. 10
2012

v.10(1)
Feb 2012

v.10(2)
Apr 2012

v.10(3)
Jul 2012

v.10(4)
Oct 2012

Vol. 9
2011

v.9(1)
Apr 2011

v.9(2)
Aug 2011

v.9(3)
Dec 2011

Vol. 8
2010

v.8(1)
Jun 2010

v.8(2)
Dec 2010

Vol. 7
2009

v.7(1)
Jun 2009

v.7(2)
Dec 2009

Vol. 6
2008

v.6(1)
Jun 2008

v.6(2)
Dec 2008

Vol. 5
2007

v.5(1)
Jun 2007

v.5(2)
Dec 2007

Vol. 4
2006

v.4(1)
Jun 2006

v.4(2)
Dec 2006

Vol. 3
2005

v.3(1)
Jun 2005

v.3(2)
Dec 2005

Vol. 2
2004

v.2(1)
Apr 2004

v.2(2)
Dec 2004

Vol. 1
2003

v.1(1)
May 2003

v.1(2)
Nov 2003

ARTICLE & TOPICS

Article Category

Browse all articles >

Browse all articles >

BROWSE ARTICLES

EDITORIAL POLICY

AUTHOR INFORMATION

Editorial Office: Room 305, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145 Fax: +82-2-957-6146 E-mail: thekasid@irjournal.org

Copyright © 2022 by Korean Association for the Study of Intestinal Diseases.

prev

next

prev

next